US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VictoryShares US Discovery Enhanced Volatility Wtd ETF

51.03

0.0000

Volume:- -

Turnover:- -

Market Cap:25.52M

PE:- -

High:51.03

Open:51.03

Low:51.03

Close:51.03

52wk High:51.03

52wk Low:51.03

Shares:500.00K

Float Shares:500.00K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures

Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

Press Release: Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

Press Release: Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Press Release: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

Press Release: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/CSF/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","market":"US","secType":"STK","nameCN":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","latestPrice":51.03,"timestamp":1787342400000,"preClose":51.03,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"08-21 16:00:00 EDT","open":51.03,"high":51.03,"low":51.03,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":51.03,"sharesOutstanding":500000,"nav":51.331892,"aum":25665950,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":0,"high":51.03,"amplitude":0,"preClose":51.03,"low":51.03,"week52Low":51.03,"pbRate":"--","week52High":51.03,"institutionHeld":0,"latestPrice":51.03,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":51.03,"prevYearClose":51.03,"prevWeekClose":51.03,"prevMonthClose":51.03,"prevQuarterClose":51.03,"fiveDayClose":51.03,"twentyDayClose":51.03,"sixtyDayClose":51.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-24","symbol":"CSF","reason":null,"defaultRemindTime":1745501400000,"announcedDate":"2025-04-23","type":"delisting","dateTimestamp":1745467200000},{"date":"2025-04-10","symbol":"CSF","amount":0.053873,"announcedDate":"2025-04-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-11"},{"date":"2025-03-10","symbol":"CSF","amount":0.09736,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"},{"date":"2024-12-12","symbol":"CSF","amount":0.194215,"announcedDate":"2024-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-13","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2024-12-13"},{"date":"2024-11-07","symbol":"CSF","amount":0.016451,"announcedDate":"2024-11-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-07","defaultRemindTime":1730989800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-08","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730955600000,"payDate":"2024-11-08"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSF\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-17","recordDate":"2017-01-19","paymentDate":"2017-01-20","value":0.0124628,"currency":"USD"},{"executeDate":"2017-02-14","recordDate":"2017-02-16","paymentDate":"2017-02-17","value":0.0180041,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-21","value":0.072161,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-19","value":0.02261,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-16","value":0.048374,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSF\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643228204","title":"Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228204","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228204?lang=en_us&edition=fundamental","pubTime":"2026-06-15 07:30","pubTimestamp":1781479800,"startTime":"0","endTime":"0","summary":"Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies ROCKVILLE, Md. and SUZHOU, Ch","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311475/0/en/Ascentage-Pharma-Presents-Multiple-Clinical-Updates-at-EHA2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","CSF","BK4139","PFS","AAPG","BK4211","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640053154","title":"Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory","url":"https://stock-news.laohu8.com/highlight/detail?id=2640053154","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640053154?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:30","pubTimestamp":1780572600,"startTime":"0","endTime":"0","summary":"CAP accreditation, widely recognized as the gold standard in laboratory quality assurance, complements CNSide Diagnostics' existing CLIA certification and further supports U.S. commercial launch of th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3306660/0/en/Plus-Therapeutics-Announces-CAP-Accreditation-of-CNSide-Diagnostics-Clinical-Laboratory.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4139","BK4007","BK4539","BK4135","LENZ","CSF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640959029","title":"Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2640959029","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640959029?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315200,"startTime":"0","endTime":"0","summary":"- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304289/36461/en/Voyager-Receives-FDA-IND-Clearance-for-VY1706-First-Gene-Therapy-Approach-to-Reducing-Tau-Production-in-the-Brain-for-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","CSF","BK4144","BK4588","LABU","AD","BK4135","BK4132","IND","BK4590","GLP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638468818","title":"Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures","url":"https://stock-news.laohu8.com/highlight/detail?id=2638468818","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638468818?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:45","pubTimestamp":1779885900,"startTime":"0","endTime":"0","summary":"ROSELAND, N.J., May  27, 2026  (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments utilizing Dynamic Pressure Sensing (DP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301977/15852/en/Milestone-Scientific-Highlights-Growing-Clinical-Adoption-and-Expanding-Physician-Acceptance-of-CompuFlo-Across-Epidural-Neuromodulation-and-Interventional-Pain-Procedures.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCS","BK4082","MLSS","CSF","BK4143"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638954070","title":"Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638954070","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638954070?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:05","pubTimestamp":1779825900,"startTime":"0","endTime":"0","summary":"Drs. Sang-Won Lee and Jaewoo Kang to share early insights from Seer's 20,000-sample collaboration with Korea University in breakfast symposium on AI-driven multi-cancer screeningREDWOOD CITY, Calif., ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3301444/0/en/Seer-to-Showcase-AI-Driven-Multi-Cancer-Screening-Approach-and-Next-Generation-Proteomics-Capabilities-at-ASMS-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","SEER","BK4132","CHAT","CSF","AGIX","AIPO","AD","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638143725","title":"Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638143725","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638143725?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:00","pubTimestamp":1779796800,"startTime":"0","endTime":"0","summary":"MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3301020/0/en/Gain-Therapeutics-Presents-Positive-Interim-Data-from-Phase-1b-Clinical-Study-of-GT-02287-at-3rd-International-GBA1-Meeting-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GANX","BK4023","CSF","BK4212","GT","BK4585","BK4119","PD","LU1169590202.USD","BK4588","LU1169589451.USD","DDC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638197205","title":"Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2638197205","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638197205?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:30","pubTimestamp":1779795000,"startTime":"0","endTime":"0","summary":"Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-makingreducing healthcare costs by 40% Presentation receives blue-ribbon recognition at the ISPOR Annual Mee","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300962/0/en/Plus-CNSide-Diagnostic-Platform-Demonstrates-Substantial-Healthcare-Cost-Reduction-in-Patients-with-Leptomeningeal-Metastases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0029874061.USD","XBI","XLV","HCSG","BK4585","BK4135","IXJ","CSF","BK4581","CNS","BK4137","LU0128526141.USD","BK4588","LABU","VHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635971914","title":"Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2635971914","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635971914?lang=en_us&edition=fundamental","pubTime":"2026-05-14 18:59","pubTimestamp":1778756340,"startTime":"0","endTime":"0","summary":"CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational developmentRobust reduct","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294711/0/en/Topline-Results-from-Phase-2-CELIA-Study-of-Diranersen-BIIB080-First-Study-to-Show-Reduction-in-Tau-Pathology-and-Cognitive-Benefit-in-Patients-with-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAIC","BK4561","ASO","MAPT","BK4110","CSF","BK4200","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242055","title":"Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242055","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242055?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:02","pubTimestamp":1778616120,"startTime":"0","endTime":"0","summary":"Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated Miv-cel pivotal trial primary analysis results in SPS de","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293353/0/en/Kyverna-Therapeutics-Announces-Initiation-of-Rolling-SPS-BLA-Submission-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4187","CSF","BK4139","BK4588","IE00B66KJ199.SGD","BK4230","IE0031619046.USD","CMC","IE00B7SZL793.SGD","IE00BHPRN162.USD","IE00B1BXHZ80.USD","LU0149725797.USD","CRS","BK4178","IE00BZ1G4Q59.USD","LU2237443622.USD","LU2746668461.USD","AAN","LU2237443465.HKD","LU2237443895.HKD","LU2237443978.SGD","BK4023","KYTX","LU0971096721.USD","IE00B19Z4B17.USD","LU2237443549.SGD","LU2746668974.SGD","BK4585","LU0963586101.USD","HCP","LU0267386448.USD","LU2237443382.USD","LU0882574139.USD","LU2065731478.USD","BK4006","BK4022","IE00BFXG1179.USD","LD","LU0170899867.USD","LU1363072403.SGD","CAR","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634882522","title":"Press Release: Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634882522","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634882522?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497200,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., May 11, 2026  -- Gain Therapeutics, Inc.  , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.\"The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 2025 related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without a GBA1 mutation. This is underscored by the promising biomarker and early clinical evidence from our ongoing Phase 1b study supporting the potential disease modifying properties of GT-02287 that we presented at AD/PD 2026 in Copenhagen this past March,\" said Gene Mack, President and CEO of Gain Therapeutics.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","CSF","LU1169590202.USD","BK4139","BK4099","03160","BK4023","PD","BK4119","TM","IND","BK4555","LU1169589451.USD","BK4585","GT","BK4212","DDC","BK4588","GANX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634881812","title":"Press Release: Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2634881812","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634881812?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497200,"startTime":"0","endTime":"0","summary":"SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback. Multiple presentations highlighting progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform to be presented at ASGCT 2026. Appointed Laura Sepp-Lorenzino, Ph.D. to Board of Directors. Cash, cash equivalents and investments of $227.6 million expected to provide operational runway into 2028. \"We continued to make steady progress across our key priorities in the first quarter of 2026. As we work with the FDA to finalize the SUNRISE--FA 2 pivotal study protocol, we are advancing site readiness and patient identification activities to ensure we are prepared to initiate the study promptly once the protocol is complete,\" said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. \"We will also have a meaningful scientific presence at ASGCT this week, where we will share updates from our LX2006 program as wel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4535","LXEO","BK4613","BK4023","BK4539","BK4585","FA","SAP","BK4139","BK4130","BK4528","CSF","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149444","title":"Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149444","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149444?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153400,"startTime":"0","endTime":"0","summary":"Enables billing under traditional Medicare and creates a pathway to ~35 million Medicare Advantage beneficiaries through future payer coverage decisionsHOUSTON, May  07, 2026 (GLOBE NEWSWIRE) -- Plus ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289865/0/en/Plus-Therapeutics-Receives-Medicare-Enrollment-Approval-for-CNSide-Diagnostic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","BK4208","BK4588","LENZ","LU0949170772.SGD","LU0738911758.USD","LU1894683264.USD","BK4231","LU1894683348.USD","LU2637428348.USD","CMS","LU2500361329.USD","LU1003077747.HKD","BK4135","BK4139","BK4007","BK4551","MAC","LU0553294199.USD","CNS","BK4080","LU2346227817.USD","LU0545039389.USD","BK4539","BK4585","LU0661504455.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630306731","title":"Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630306731","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630306731?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:30","pubTimestamp":1777375800,"startTime":"0","endTime":"0","summary":"Expands access by 6 million covered lives, advancing commercial momentum for CNSide in metastatic CNS cancersHOUSTON, April  28, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsid","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/28/3282472/0/en/Plus-Therapeutics-Secures-Blue-Shield-of-California-Coverage-for-CNSide-Cerebrospinal-Fluid-Assay-for-Metastatic-CNS-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4007","CSF","BK4135","CNS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629009484","title":"Press Release: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629009484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629009484?lang=en_us&edition=fundamental","pubTime":"2026-04-23 13:00","pubTimestamp":1776920400,"startTime":"0","endTime":"0","summary":"Geneva, Switzerland, April 23, 2026 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2 2026. NTX-253 is an investigational potent, selective, orally available positive allosteric modulator  of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The study is designed to generate a robust early-stage clinical data package assessing safety, tolerability, and pharmacokinetics  across both healthy adult participants and those with stable schizophrenia.The clinical study includes a multi-part, ascending-dose design intended to efficiently characterize NTX-253's clinical profile and support subsequent patient-focused development. The study includes both single ascending dose  and multiple ascending dose  components,","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTX","ADXN","PAM","CSF","BK4139","BK4081","BK4563","BK4218","BK4181","PK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625949165","title":"Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2625949165","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625949165?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:30","pubTimestamp":1775647800,"startTime":"0","endTime":"0","summary":"HOUSTON, April  08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/08/3270005/0/en/Plus-Therapeutics-Granted-U-S-FDA-Orphan-Drug-Designation-to-REYOBIQ-in-Pediatric-Malignant-Gliomas.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","IND","BK4539","LENZ","BK4202","BK4135","CSF","BK4183","LABU","BK4585","BK4139","BK4588","IE0009354923.USD","NCI","CNS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625958701","title":"Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption","url":"https://stock-news.laohu8.com/highlight/detail?id=2625958701","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625958701?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:30","pubTimestamp":1775561400,"startTime":"0","endTime":"0","summary":"New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization trackingHOUSTON, April  07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/07/3268999/0/en/Plus-Therapeutics-Receives-AMA-PLA-Code-for-CNSide-CSF-Tumor-Cell-Enumeration-Test-Advancing-Reimbursement-and-U-S-Commercial-Adoption.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPT","BK4135","BK4585","BK4215","AMA","LENZ","BK4539","CSF","BK4139","BK4588","BK4007","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624062105","title":"Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives","url":"https://stock-news.laohu8.com/highlight/detail?id=2624062105","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624062105?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:30","pubTimestamp":1775129400,"startTime":"0","endTime":"0","summary":"HOUSTON, April  02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc.(Nasdaq:PSTV) (“Plus” or the “Company”), today announces a new payer coverage ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/02/3267245/0/en/Plus-Therapeutics-Secures-Highmark-Coverage-for-CNSide-CSF-Assay-Expanding-Reimbursement-to-75-Million-Covered-Lives.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CSF","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622518778","title":"Press Release: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622518778","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622518778?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., March 26, 2026  -- Gain Therapeutics, Inc.  , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update.Mr. Mack continued, \"We will continue to follow patients in the Phase 1b nine-month extension study that is expected to complete in September 2026 and look forward to presenting longer-term follow up at additional scientific conferences throughout the balance of the year. To date, MDS-UPDRS scores remained stable and durable across the overall study population after 150 days of treatment with GT-02287 and are becoming more encouraging with the passage of time. We believe the totality of the data continues to support the potential of GT-02287 in both idiopathic and GBA1 Parkinson's disease and we hope to one day shift the treatment paradigm away from symptomatic relief ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GANX","IND","BK4588","BK4212","BK4099","BK4555","DDC","R","BK4139","BK4585","BK4023","GT","03160","LU1169589451.USD","BK4022","PD","BK4604","BK4232","BK4119","CSF","TM","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622008319","title":"Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622008319","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622008319?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:50","pubTimestamp":1774453800,"startTime":"0","endTime":"0","summary":"First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that leverag","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262412/0/en/Denali-Therapeutics-Announces-U-S-FDA-Approval-of-AVLAYAH-tividenofusp-alfa-eknm-for-Treatment-of-Hunter-Syndrome-MPS-II.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","LABU","BK4139","BK4585","TV","BK4007","BK4100","BK4081","EMA","BK4588","BK4539","BBB","LENZ","BK4115"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621261758","title":"Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621261758","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621261758?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:05","pubTimestamp":1774022700,"startTime":"0","endTime":"0","summary":"Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March  20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/20/3259865/0/en/Results-from-Real-World-Long-Term-Treatment-Persistence-with-LEQEMBI-lecanemab-irmb-in-the-United-States-Presented-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCI","LU1169589451.USD","BK4132","PD","CSF","LU1169590202.USD","AD","UBCP","BK4023","BK4211","CDR","BK4080"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":65,"code":"91000000","status":"200"}]}}